Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.

Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS.

N Engl J Med. 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626.

PMID:
31722153
2.

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib plus Dexamethasone in Relapsed Multiple Myeloma.

Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach JP, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS.

Clin Cancer Res. 2019 Oct 31. pii: clincanres.0647.2019. doi: 10.1158/1078-0432.CCR-19-0647. [Epub ahead of print]

PMID:
31672767
3.

Increase in seed tannin extractability and oxidation using a freeze-thaw treatment in cool-climate grown red (Vitis vinifera L.) cultivars.

VanderWeide J, Forte A, Peterlunger E, Sivilotti P, Medina-Meza IG, Falchi R, Rustioni L, Sabbatini P.

Food Chem. 2020 Mar 5;308:125571. doi: 10.1016/j.foodchem.2019.125571. Epub 2019 Oct 16.

PMID:
31655480
4.

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.

O'Cearbhaill RE, Deng W, Chen LM, Lucci JA 3rd, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ.

Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31536-7. doi: 10.1016/j.ygyno.2019.09.015. [Epub ahead of print]

PMID:
31653510
5.

Engaging Community-Based Cancer Physicians: Experience of the Memorial Sloan Kettering Cancer Center Cancer Alliance.

Lipitz-Snyderman A, Kennington J, Hogan B, Korenstein D, Kalman L, Nair S, Yu P, Sabbatini P, Pfister D.

J Natl Compr Canc Netw. 2019 Sep 1;17(9):1083-1087. doi: 10.6004/jnccn.2019.7295.

PMID:
31487684
6.

Understanding kaolin effects on grapevine leaf and whole-canopy physiology during water stress and re-watering.

Frioni T, Saracino S, Squeri C, Tombesi S, Palliotti A, Sabbatini P, Magnanini E, Poni S.

J Plant Physiol. 2019 Nov;242:153020. doi: 10.1016/j.jplph.2019.153020. Epub 2019 Aug 16.

PMID:
31450036
7.

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA III, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):896-909. doi: 10.6004/jnccn.2019.0039.

PMID:
31390583
8.

Metabolic and transcriptional changes associated with the use of Ascophyllum nodosum extracts as tools to improve the quality of wine grapes (Vitis vinifera cv. Sangiovese) and their tolerance to biotic stress.

Frioni T, Tombesi S, Quaglia M, Calderini O, Moretti C, Poni S, Gatti M, Moncalvo A, Sabbatini P, Berrìos JG, Palliotti A.

J Sci Food Agric. 2019 Nov;99(14):6350-6363. doi: 10.1002/jsfa.9913. Epub 2019 Aug 6.

PMID:
31273796
9.

A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.

Moore KN, Gunderson CC, Sabbatini P, McMeekin DS, Mantia-Smaldone G, Burger RA, Morgan MA, Kapoun AM, Brachmann RK, Stagg R, Farooki A, O'Cearbhaill RE.

Gynecol Oncol. 2019 Aug;154(2):294-301. doi: 10.1016/j.ygyno.2019.04.001. Epub 2019 Jun 4.

PMID:
31174889
10.

Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.

Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, Sabbatini P, Aghajanian C, Cadoo KA, Zamarin D.

Gynecol Oncol. 2019 Feb;152(2):251-258. doi: 10.1016/j.ygyno.2018.11.025. Epub 2018 Nov 22.

11.

Enhancement of Fruit Technological Maturity and Alteration of the Flavonoid Metabolomic Profile in Merlot ( Vitis vinifera L.) by Early Mechanical Leaf Removal.

VanderWeide J, Medina-Meza IG, Frioni T, Sivilotti P, Falchi R, Sabbatini P.

J Agric Food Chem. 2018 Sep 19;66(37):9839-9849. doi: 10.1021/acs.jafc.8b02709. Epub 2018 Sep 5.

PMID:
30130400
12.

Changes in Within-Shoot Carbon Partitioning in Pinot Noir Grapevines Subjected to Early Basal Leaf Removal.

Frioni T, Acimovic D, Tombesi S, Sivilotti P, Palliotti A, Poni S, Sabbatini P.

Front Plant Sci. 2018 Aug 3;9:1122. doi: 10.3389/fpls.2018.01122. eCollection 2018.

13.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1.

PMID:
30068706
14.

A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.

LaVigne K, Hyman DM, Zhou QC, Iasonos A, Tew WP, Aghajanian C, Makker V, Hensley ML, Konner J, Grisham RN, Cangemi N, Soldan K, Spriggs DR, Sabbatini PJ, OʼCearbhaill RE.

Int J Gynecol Cancer. 2018 Jul;28(6):1176-1182. doi: 10.1097/IGC.0000000000001280.

15.

Utilization of a freeze-thaw treatment to enhance phenolic ripening and tannin oxidation of grape seeds in red (Vitis vinifera L.) cultivars.

Rustioni L, Cola G, VanderWeide J, Murad P, Failla O, Sabbatini P.

Food Chem. 2018 Sep 1;259:139-146. doi: 10.1016/j.foodchem.2018.03.120. Epub 2018 Mar 27.

PMID:
29680036
16.

Slow Off-Rate Modified Aptamer (SOMAmer) as a Novel Reagent in Immunoassay Development for Accurate Soluble Glypican-3 Quantification in Clinical Samples.

Duo J, Chiriac C, Huang RY, Mehl J, Chen G, Tymiak A, Sabbatini P, Pillutla R, Zhang Y.

Anal Chem. 2018 Apr 17;90(8):5162-5170. doi: 10.1021/acs.analchem.7b05277. Epub 2018 Apr 6.

PMID:
29605994
17.

Correction to Combined Effects of Early Season Leaf Removal and Climatic Conditions on Aroma Precursors in Sauvignon Blanc Grapes.

Sivilotti P, Falchi R, Herrera JC, Škvarč B, Butinar L, Sternad Lemut M, Bubola M, Sabbatini P, Lisjak K, Vanzo A.

J Agric Food Chem. 2017 Nov 8;65(44):9815. doi: 10.1021/acs.jafc.7b04861. Epub 2017 Oct 25. No abstract available.

PMID:
29068211
18.

OncoKB: A Precision Oncology Knowledge Base.

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N.

JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.

19.

Combined Effects of Early Season Leaf Removal and Climatic Conditions on Aroma Precursors in Sauvignon Blanc Grapes.

Sivilotti P, Falchi R, Herrera JC, Škvarč B, Butinar L, Sternad Lemut M, Bubola M, Sabbatini P, Lisjak K, Vanzo A.

J Agric Food Chem. 2017 Sep 27;65(38):8426-8434. doi: 10.1021/acs.jafc.7b03508. Epub 2017 Sep 12. Erratum in: J Agric Food Chem. 2017 Nov 8;65(44):9815.

PMID:
28851221
20.

Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Aug 4;23(8):1004. doi: 10.1038/nm0817-1004c. No abstract available.

PMID:
28777785
21.

Grape Metabolic Response to Postveraison Water Deficit Is Affected by Interseason Weather Variability.

Herrera JC, Hochberg U, Degu A, Sabbatini P, Lazarovitch N, Castellarin SD, Fait A, Alberti G, Peterlunger E.

J Agric Food Chem. 2017 Jul 26;65(29):5868-5878. doi: 10.1021/acs.jafc.7b01466. Epub 2017 Jul 12.

PMID:
28661689
22.

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Zehir A, Benayed R, Shah RH, Syed A, Middha S, Kim HR, Srinivasan P, Gao J, Chakravarty D, Devlin SM, Hellmann MD, Barron DA, Schram AM, Hameed M, Dogan S, Ross DS, Hechtman JF, DeLair DF, Yao J, Mandelker DL, Cheng DT, Chandramohan R, Mohanty AS, Ptashkin RN, Jayakumaran G, Prasad M, Syed MH, Rema AB, Liu ZY, Nafa K, Borsu L, Sadowska J, Casanova J, Bacares R, Kiecka IJ, Razumova A, Son JB, Stewart L, Baldi T, Mullaney KA, Al-Ahmadie H, Vakiani E, Abeshouse AA, Penson AV, Jonsson P, Camacho N, Chang MT, Won HH, Gross BE, Kundra R, Heins ZJ, Chen HW, Phillips S, Zhang H, Wang J, Ochoa A, Wills J, Eubank M, Thomas SB, Gardos SM, Reales DN, Galle J, Durany R, Cambria R, Abida W, Cercek A, Feldman DR, Gounder MM, Hakimi AA, Harding JJ, Iyer G, Janjigian YY, Jordan EJ, Kelly CM, Lowery MA, Morris LGT, Omuro AM, Raj N, Razavi P, Shoushtari AN, Shukla N, Soumerai TE, Varghese AM, Yaeger R, Coleman J, Bochner B, Riely GJ, Saltz LB, Scher HI, Sabbatini PJ, Robson ME, Klimstra DS, Taylor BS, Baselga J, Schultz N, Hyman DM, Arcila ME, Solit DB, Ladanyi M, Berger MF.

Nat Med. 2017 Jun;23(6):703-713. doi: 10.1038/nm.4333. Epub 2017 May 8. Erratum in: Nat Med. 2017 Aug 4;23 (8):1004.

23.

Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.

Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS.

Lancet Oncol. 2017 Jun;18(6):779-791. doi: 10.1016/S1470-2045(17)30279-6. Epub 2017 Apr 21.

24.

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Morgan RJ Jr, Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Behbakht K, Chen LM, Copeland L, Crispens MA, DeRosa M, Dorigo O, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Percac-Lima S, Pineda M, Plaxe SC, Powell MA, Ratner E, Remmenga SW, Rose PG, Sabbatini P, Santoso JT, Werner TL, Burns J, Hughes M.

J Natl Compr Canc Netw. 2016 Sep;14(9):1134-63.

PMID:
27587625
25.

Effects of a warming trend on cool climate viticulture in Michigan, USA.

Schultze SR, Sabbatini P, Luo L.

Springerplus. 2016 Jul 19;5(1):1119. doi: 10.1186/s40064-016-2777-1. eCollection 2016.

26.

Impact of Leaf Removal, Applied Before and After Flowering, on Anthocyanin, Tannin, and Methoxypyrazine Concentrations in 'Merlot' (Vitis vinifera L.) Grapes and Wines.

Sivilotti P, Herrera JC, Lisjak K, Baša Česnik H, Sabbatini P, Peterlunger E, Castellarin SD.

J Agric Food Chem. 2016 Jun 8;64(22):4487-96. doi: 10.1021/acs.jafc.6b01013. Epub 2016 May 27.

PMID:
27180819
27.

A Phase I Study of Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission.

O'Cearbhaill RE, Ragupathi G, Zhu J, Wan Q, Mironov S, Yang G, Spassova MK, Iasonos A, Kravetz S, Ouerfelli O, Spriggs DR, Danishefsky SJ, Sabbatini PJ.

Cancers (Basel). 2016 Apr 22;8(4). pii: E46. doi: 10.3390/cancers8040046.

28.

A Phase 2, Single Arm Study of Iniparib in Patients With BRCA1 or BRCA2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.

Bell-McGuinn KM, Konner JA, Tew WP, Hensley ML, Iasonos A, Charpentier E, Mironov S, Sabbatini P, Aghajanian C.

Int J Gynecol Cancer. 2016 Feb;26(2):255-60. doi: 10.1097/IGC.0000000000000591.

29.

Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.

Kashyap MK, Kumar D, Jones H, Amaya-Chanaga CI, Choi MY, Melo-Cardenas J, Ale-Ali A, Kuhne MR, Sabbatini P, Cohen LJ, Shelat SG, Rassenti LZ, Kipps TJ, Cardarelli PM, Castro JE.

Oncotarget. 2016 Jan 19;7(3):2809-22. doi: 10.18632/oncotarget.6465.

30.

Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D.

J Clin Oncol. 2016 Feb 20;34(6):557-65. doi: 10.1200/JCO.2015.63.0830. Epub 2015 Dec 7. Erratum in: J Clin Oncol. 2016 Jun 20;34(18):2198. Erratum in: J Clin Oncol. 2019 Feb 20;37(6):528.

31.

Concepts and Molecular Aspects in the Polypharmacology of PARP-1 Inhibitors.

Passeri D, Camaioni E, Liscio P, Sabbatini P, Ferri M, Carotti A, Giacchè N, Pellicciari R, Gioiello A, Macchiarulo A.

ChemMedChem. 2016 Jun 20;11(12):1219-26. doi: 10.1002/cmdc.201500391. Epub 2015 Oct 1. Review.

PMID:
26424664
32.

Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials.

Hyman DM, Solit DB, Arcila ME, Cheng DT, Sabbatini P, Baselga J, Berger MF, Ladanyi M.

Drug Discov Today. 2015 Dec;20(12):1422-8. doi: 10.1016/j.drudis.2015.08.005. Epub 2015 Aug 28.

33.

Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial.

Tsuji T, Sabbatini P, Jungbluth AA, Ritter E, Pan L, Ritter G, Ferran L, Spriggs D, Salazar AM, Gnjatic S.

Cancer Immunol Res. 2013 Nov;1(5):340-50. doi: 10.1158/2326-6066.CIR-13-0089. Epub 2013 Sep 16.

34.

Ovarian cancer, version 2.2013.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M; National comprehensive cancer networks.

J Natl Compr Canc Netw. 2013 Oct 1;11(10):1199-209.

PMID:
24142821
35.

Synthesis and quantitative structure-property relationships of side chain-modified hyodeoxycholic acid derivatives.

Sabbatini P, Filipponi P, Sardella R, Natalini B, Nuti R, Macchiarulo A, Pellicciari R, Gioiello A.

Molecules. 2013 Aug 30;18(9):10497-513. doi: 10.3390/molecules180910497.

36.

1,4-Benzothiazine ATP-sensitive potassium channel openers: modifications at the C-2 and C-6 positions.

Martelli A, Manfroni G, Sabbatini P, Barreca ML, Testai L, Novelli M, Sabatini S, Massari S, Tabarrini O, Masiello P, Calderone V, Cecchetti V.

J Med Chem. 2013 Jun 13;56(11):4718-28. doi: 10.1021/jm400435a. Epub 2013 May 28.

PMID:
23662847
37.

Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study.

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, Baumann KH, Kurzeder C, Schmalfeldt B, Cibula D, Bidzinski M, Casado A, Martoni A, Colombo N, Holloway RW, Selvaggi L, Li A, del Campo J, Cwiertka K, Pinter T, Vermorken JB, Pujade-Lauraine E, Scartoni S, Bertolotti M, Simonelli C, Capriati A, Maggi CA, Berek JS, Pfisterer J.

J Clin Oncol. 2013 Apr 20;31(12):1554-61. doi: 10.1200/JCO.2012.46.4057. Epub 2013 Mar 11.

38.

Ovarian cancer, version 3.2012.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Burger RA, Castells M, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray H, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Santoso JT, Schilder RJ, Schink J, Teng N, Werner TL, Hughes M, Dwyer MA; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Nov 1;10(11):1339-49.

PMID:
23138163
39.

A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission.

Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I, Reddy JC.

Clin Cancer Res. 2012 Dec 1;18(23):6509-18. doi: 10.1158/1078-0432.CCR-12-1796. Epub 2012 Oct 2.

40.

Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.

Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S.

Clin Cancer Res. 2012 Dec 1;18(23):6497-508. doi: 10.1158/1078-0432.CCR-12-2189. Epub 2012 Oct 2.

41.

Early postoperative CT as a prognostic biomarker in patients with advanced ovarian, tubal, and primary peritoneal cancer deemed optimally debulked at primary cytoreductive surgery.

Lakhman Y, Akin O, Sohn MJ, Zheng J, Moskowitz CS, Iyer RB, Barakat RR, Sabbatini PJ, Chi DS, Hricak H.

AJR Am J Roentgenol. 2012 Jun;198(6):1453-9. doi: 10.2214/AJR.11.7257.

PMID:
22623562
42.

Avicholic Acid: A Lead Compound from Birds on the Route to Potent TGR5 Modulators.

Pellicciari R, Gioiello A, Sabbatini P, Venturoni F, Nuti R, Colliva C, Rizzo G, Adorini L, Pruzanski M, Roda A, Macchiarulo A.

ACS Med Chem Lett. 2012 Feb 6;3(4):273-7. doi: 10.1021/ml200256d. eCollection 2012 Apr 12.

43.

Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS.

Gynecol Oncol. 2012 Jun;125(3):621-4. doi: 10.1016/j.ygyno.2012.03.027. Epub 2012 Mar 21.

PMID:
22446622
44.

Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission.

Iasonos A, Sabbatini P, Spriggs DR, Aghajanian CA, O'Cearbhaill RE, Hensley ML, Thaler HT.

Int J Gynecol Cancer. 2012 Jan;22(1):63-9. doi: 10.1097/IGC.0b013e31822e29aa.

45.

Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma.

Konner J, Grisham RN, Park J, O'Connor OA, Cropp G, Johnson R, Hannah AL, Hensley ML, Sabbatini P, Mironov S, Danishefsky S, Hyman D, Spriggs DR, Dupont J, Aghajanian C.

Invest New Drugs. 2012 Dec;30(6):2294-302. doi: 10.1007/s10637-011-9765-7. Epub 2011 Nov 10. Erratum in: Invest New Drugs. 2012 Dec;30(6):2450. Miranov, Svetlana [corrected to Mironov, Svetlana].

46.

Phase II study of intraperitoneal paclitaxel plus cisplatin and intravenous paclitaxel plus bevacizumab as adjuvant treatment of optimal stage II/III epithelial ovarian cancer.

Konner JA, Grabon DM, Gerst SR, Iasonos A, Thaler H, Pezzulli SD, Sabbatini PJ, Bell-McGuinn KM, Tew WP, Hensley ML, Spriggs DR, Aghajanian CA.

J Clin Oncol. 2011 Dec 10;29(35):4662-8. doi: 10.1200/JCO.2011.36.1352. Epub 2011 Nov 7.

47.

Eribulin mesylate (halichondrin B analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a 2-cohort, phase 2 study.

Hensley ML, Kravetz S, Jia X, Iasonos A, Tew W, Pereira L, Sabbatini P, Whalen C, Aghajanian CA, Zarwan C, Berlin S.

Cancer. 2012 May 1;118(9):2403-10. doi: 10.1002/cncr.26569. Epub 2011 Sep 20.

48.

Abagovomab: an anti-idiotypic CA-125 targeted immunotherapeutic agent for ovarian cancer.

Grisham RN, Berek J, Pfisterer J, Sabbatini P.

Immunotherapy. 2011 Feb;3(2):153-62. doi: 10.2217/imt.10.100. Review.

49.

Abagovomab for ovarian cancer.

Pfisterer J, Harter P, Simonelli C, Peters M, Berek J, Sabbatini P, du Bois A.

Expert Opin Biol Ther. 2011 Mar;11(3):395-403. doi: 10.1517/14712598.2011.553598. Epub 2011 Jan 18. Review.

PMID:
21241213
50.

Epithelial ovarian cancer.

Morgan RJ Jr, Alvarez RD, Armstrong DK, Boston B, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson D, Gray HJ, Grigsby PW, Hakam A, Havrilesky LJ, Johnston C, Lele S, Matulonis UA, O'Malley DM, Penson RT, Remmenga SW, Sabbatini P, Schilder RJ, Schink JC, Teng N, Werner TL; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2011 Jan;9(1):82-113. No abstract available.

PMID:
21233246

Supplemental Content

Loading ...
Support Center